Innovation Pharmaceuticals (OTCMKTS:IPIX) Stock Rockets After The News: What Next?
Innovation Pharmaceuticals (OTCMKTS:IPIX) jumped 18% after offering additional information about the randomized, placebo-controlled, double blinds phase II clinical study status evaluating Brilacidin in moderate-to-severed COVID-19 treatment in hospitalized patients. The company is advancing Brilacidin for COVID-19 treatment under a fast track designation. Enrollment in the study ended in June 2021, with the last patient follow-up visit occurring on July 30, 2021. Notably, the subject database is still blinded, focusing on…